Gene · 203068
TUBB: tubulin beta class I
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBB: tubulin beta class I. Genes, record 203068. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/203068
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P07437 | Tubulin beta chain | 444 | 21 | Ensembl, GeneID, HGNC |
Source UniProt
Patents140
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 68528 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68530 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68539 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68542 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68543 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68544 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68551 | P07437 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68555 | P07437 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6397 | P07437 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5111 | P07437 | Espacenet |
1 to 10 of 140
See all 140 patentsDrugs91
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-751 | CHEMBL20684 | Tubulin beta inhibitor | INHIBITOR | ChEMBL |
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 91
See all 91 drugsTrials8,740
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,740
See all 8,740 trialsNIH grants1,820
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBB papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| R01NS058721 | ACC: Callosal Agenesis as a Window into Common Neurodevelopmental Disorders | 7 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 6 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 4 | 2025 |
| KL2TR001879 | Institutional Career Development Core | 3 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 3 | 2025 |
1 to 10 of 1,820Source NIH's project files
See all 1,820 nih grantsPapers2,200
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and evaluation of candidate sperm proteins associated with cryopreservation-induced changes in semen quality in Thai native roosters. | Poult Sci | 2026 | 42785075 | PubTator, text mining | PubMed |
| KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin. | Biochem Pharmacol | 2026 | 42685875 | PubTator, text mining | PubMed |
| A Novel Constitutional TUBB Variant Associated With Familial Malformations of Cortical Development. | Am J Med Genet A | 2026 | 42631447 | PubTator, text mining | PubMed |
| Exosomal gene-based predictive model and therapeutic target identification for Alzheimer's disease: A bioinformatics analysis. | PLoS One | 2026 | 42475384 | PubTator, text mining | PubMed |
| Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study. | Arthritis Res Ther | 2026 | 42387612 | PubTator, text mining | PubMed |
| Multi-omics profiling characterizes the primary cilium-related molecular regulatory landscape in systemic lupus erythematosus. | Analyst | 2026 | 42312723 | PubTator, text mining | PubMed |
| Exploring the Potential of Calebin-A in Targeting Obesity-Related Genes and Pathways. | J Cell Mol Med | 2026 | 42286733 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis-based Mendelian randomization identifies association of DNA repair-related genes with oral cancer. | Cancer Biomark | 2026 | 42257465 | PubTator, text mining | PubMed |
| Genetic Identification of Potential Drug Targets for Dental Caries: A Mendelian Randomization Study. | Health Sci Rep | 2026 | 42163948 | PubTator, text mining | PubMed |
| Unraveling novel therapeutic targets for diffuse large B-cell lymphoma: a plasma multi-omics study. | Front Pharmacol | 2026 | 42147334 | PubTator, text mining | PubMed |
1 to 10 of 2,200
See all 2,200 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/203068
GET https://conductscience.org/api/genes/v1/203068/patents?page=2